21:59 , Jul 11, 2019 |  BC Innovations  |  Targets & Mechanisms

The tumor stroma rises as the newest source of immuno-oncology targets

With a spate of therapies entering the clinic, the next frontier in the fight against resistance to checkpoint inhibitors will be the stroma. The lead target marks a resurgence of interest in TGFβ, and behind...
00:35 , Feb 1, 2019 |  BC Innovations  |  Tools & Techniques

TMB needs company

Tumor mutation burden is looking less like a magic bullet and more like just one of at least three variables that could jointly predict responses to checkpoint inhibitors. Combining TMB measurements with markers of T...
18:03 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Genentech reports detailed OS data for Tecentriq combo in first-line non-squamous NSCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported additional survival data from the Phase III IMpower150 trial evaluating Tecentriq atezolizumab in 1,202 chemotherapy-naïve patients with advanced stage IV non-squamous non-small cell lung cancer (NSCLC)....
20:45 , Dec 22, 2017 |  BioCentury  |  Product Development

Beyond PD-L1 assays

Data from Genentech Inc.’s Phase III IMpower150 trial of Tecentriq atezolizumab in first-line non-small cell lung cancer provides the company with its first hard data showing what work lies ahead before it will be ready...
03:56 , Dec 15, 2017 |  BC Week In Review  |  Clinical News

Genentech reports detailed data for Tecentriq in first-line NSCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported detailed data from the Phase III IMpower150 trial of Tecentriq atezolizumab (MPDL3280A, RG7446) as first-line treatment of advanced stage IV non-squamous non-small cell lung cancer (NSCLC),...
22:11 , Dec 7, 2017 |  BC Extra  |  Clinical News

Genentech reports detailed data for Tecentriq in first-line NSCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported detailed data from the Phase III IMpower150 trial of Tecentriq atezolizumab as first-line treatment of advanced stage IV non-squamous non-small cell lung cancer, including results from...
01:05 , Apr 21, 2017 |  BC Innovations  |  Product R&D

Making marks at AACR

Biomarkers that could stratify patients, point to treatment combinations or predict toxicity were a major part of the conversation at this year’s AACR conference, where they emerged as potential difference makers for a range of...
22:27 , Mar 16, 2017 |  BC Innovations  |  Product R&D

Neo wave

The central thesis in the increasingly hot field of neoantigens is to pick mutations from patient tumors and turn them into personalized immunotherapies. While companies are staking out their space by defining how they will...
07:00 , Jun 27, 2016 |  BC Week In Review  |  Financial News

Affiris completes venture financing

Affiris AG , Vienna, Austria   Business: Neurology, Cardiovascular, Endocrine/Metabolic   Date completed: 2016-06-23   Type: Venture financing   Raised: EUR10 million ($11.3 million)   Investors: Santo Holding; MIG Funds; FCPG Affi  ...
00:19 , Jun 24, 2016 |  BC Extra  |  Financial News

Affiris raises EUR 10M

Affiris AG (Vienna, Austria) said it raised EUR 10 million ($11.3 million) from FCPB Affi GmbH and existing investors Santo Holding GmbH and MIG Funds. Affiris expects Phase I data in 1Q17 for AT04A and...